Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors)

BACKGROUND: Reduction in cardiovascular death and hospitalization for heart failure (HHF) was recently reported with the sodium-glucose cotransporter-2 inhibitor (SGLT-2i) empagliflozin in patients with type 2 diabetes mellitus who have atherosclerotic cardiovascular disease. We compared HHF and dea...

Descripción completa

Detalles Bibliográficos
Autores principales: Kosiborod, Mikhail, Cavender, Matthew A., Fu, Alex Z., Wilding, John P., Khunti, Kamlesh, Holl, Reinhard W., Norhammar, Anna, Birkeland, Kåre I., Jørgensen, Marit Eika, Thuresson, Marcus, Arya, Niki, Bodegård, Johan, Hammar, Niklas, Fenici, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Original Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515629/
https://www.ncbi.nlm.nih.gov/pubmed/28522450
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.029190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515629/
https://www.ncbi.nlm.nih.gov/pubmed/28522450
http://dx.doi.org/10.1161/CIRCULATIONAHA.117.029190

Ejemplares similares